JBIO: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-95,478	-70,303
Change in fair value of convertible notes payable	21,584	21,584
Stock-based compensation	10,613	6,318
Non-cash lease expense	57	74
Accretion/amortization on investments	174	-
Depreciation expense	17	5
Prepaid expenses and other current assets	1,771	1,358
Other assets	-	-88
Accounts payable	60	4,938
Accrued expenses and other current liabilities	7,440	2,862
Operating lease liabilities	68	-
Related party accrued expenses and other current liabilities	-3,456	-3,124
Net cash used in operating activities	-61,040	-38,916
Purchases of investments	148,592	-
Payment of security deposit	59	-
Purchases of property and equipment	193	136
Net cash used in investing activities	-148,844	-136
Proceeds from the pre-closing financing, net of 14,548 of offering costs	190,452	190,452
Cash acquired in connection with the reverse recapitalization	156	156
Net cash provided by financing activities	190,608	190,608
Effect on exchange rates on cash and cash equivalents	-4	-
Net (decrease) increase in cash and cash equivalents	-19,280	151,556
Cash and cash equivalents at beginning of period	69,386	-
Cash and cash equivalents at end of period	50,106	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

JBIO: the cashflow